Harrisvaccines has been named to provide RNA process development for a trivalent vaccine against the hemorrhagic fever-causing filoviruses known as Ebola virus and Marburg virus.

The project is funded by a $15 million contract overseen by the Chemical Biological Medical Systems-Joint Vaccine Acquisition Program, which are responsible for developing, acquiring and stockpiling Food and Drug Administration-approved vaccines to protect against biological weapons. The filovirus project marks Harrisvaccines’ first foray into human vaccines.